With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

With a new investment in its two manufacturing sites in Ireland, Eli Lilly continues implementing the largest expansion ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

U.S. pharmaceutical giant Eli Lilly named a new chief financial officer on Monday during a critical time for the company's ...

Lucas Montarce's career path at the company is similar to that of his predecessor, Anat Ashkenazi.

Eli Lilly and Company is expanding its manufacturing footprint in Ireland with a $1.8B investment to boost production of ...

Chicago, IL – September 12, 2024 – Zacks Equity Research shares Eli Lilly LLY as the Bull of the Day and Hertz Global HTZ as ...

Eli Lilly has been an innovative force in medicine ... However, I'd encourage investors to zoom out and think long-term here. Lilly has a history of not only paying a dividend, but raising it.

This additional investment is part of Eli Lilly's most ambitious manufacturing expansion agenda in the company’s history.